Of the cholinesterase inhibitors, to date only rivastigmine, tacrine [68], memantine [62], donepezil, and galantamine have been approved for the treatment of AD [67]; aducanumab is the only monoclonal antibody immunotherapy so far (2003) approved by the FDA [68,69,70]. The gene discussed is BCHE; the disease is Alzheimer disease.